Finally, few studies have previously reported that CIM did not impact the antitumor effects of CIS in vitro or in vivo in OCT2 expressing cancer models; however, those studies evaluated the impact of CIM at only one or two concentrations or dose levels [10,11]. This evidence concerns the gene SLC22A2 and in situ carcinoma.